Is stem cell therapy generally scientifically recognised?

Only partly. What is recognised and established is above all haematopoietic stem cell transplantation for defined blood and immune disorders. Many other commercially advertised “stem cell therapies” - for example against osteoarthritis, ageing, or neurological diseases - are by contrast experimental or unproven and not approved.

Why do authorities warn against some stem cell offerings?

Because many offerings are marketed without robust proof of efficacy and outside authorised clinical trials. The FDA and Paul-Ehrlich-Institut/EMA point to real risks such as severe infections, tumour formation, or blindness, as well as financial burden and false hope. Payment outside a study is, according to the FDA, a warning sign.

What should I do if I am offered a stem cell treatment?

This page does not replace medical advice. As a general principle: check the approval status, ask whether it is an authorised clinical trial, and discuss the offering with independent specialist physicians before making a decision.

Regenerative Medicine7 min readLast reviewed: June 2026

Stem Cell Therapy: Benefits and Risks at a Glance

“Stem cell therapy” is an umbrella term that covers very different things. On one side stands the strictly regulated stem cell transplantation for blood and immune disorders, established for decades. On the other side, commercial clinics - often abroad or online - advertise stem cell “treatments” for osteoarthritis, autism, ageing, or neurological conditions, for which there is no robust proof of efficacy. This article cleanly separates the two: it explains what stem cells are actually approved and effective for, what research really shows for new applications, what the regulatory status looks like in Europe and the United States, and what concrete risks the unregulated grey market carries. This is a purely educational text, not medical advice.

Machine-assisted translation. The German original is the authoritative version.

Key points

Haematopoietic stem cell transplantation is an established, indication-bound standard therapy for certain blood and immune disorders - with clear benefit, but also serious risks.
For most widely advertised stem cell applications (osteoarthritis, anti-ageing, neurological conditions), robust human evidence is lacking; much is experimental or unproven.
In regulatory terms, only blood-forming stem cell products are approved for blood/immune disorders (FDA); in the EU, manipulated stem cells are ATMP and must be approved centrally.
The FDA and the Paul-Ehrlich-Institut/EMA explicitly warn against commercially marketed, unapproved stem cell offerings outside authorised studies.
“Stem cell tourism” carries documented risks up to and including blindness, tumour formation, and severe infections - medical advice before any decision is essential.

What stem cells are - and what stem cell therapy actually means

Stem cells are unspecialised body cells with two special properties: they can renew themselves and differentiate into specialised cell types. From this stems the hope of being able to replace or repair damaged tissue. The crucial point, however, is that “stem cells” are not a uniform product: haematopoietic (blood-forming) stem cells, mesenchymal stem/stromal cells, embryonic stem cells, and induced pluripotent stem cells differ fundamentally in origin, behaviour, and safety profile.

In practice, only a single application today truly rests on solid ground: haematopoietic stem cell transplantation (HSCT), colloquially known as bone marrow or blood stem cell transplantation. Here, blood-forming stem cells are transferred to replace bone marrow that is diseased or destroyed by chemotherapy. Everything else - such as injections of mesenchymal cells into joints, blood, or the nervous system against a broad spectrum of diseases - is largely experimental or unproven, even when it is commercially marketed as “stem cell therapy”.

Stem cells can renew themselves and differentiate into specialised cells
“Stem cells” is an umbrella term for very different cell types with different levels of risk
What is firmly established is above all blood-forming (haematopoietic) stem cell transplantation
Many commercial offerings use the term without resting on comparable evidence

The established application: haematopoietic stem cell transplantation

HSCT has been a recognised part of medicine for decades and is standard therapy for certain diseases. Established indications include acute leukaemias (AML, ALL), certain lymphomas, multiple myeloma, and myelodysplastic syndromes, as well as non-malignant conditions such as aplastic anaemia, severe congenital immunodeficiencies (SCID), thalassaemia, and sickle cell disease. A distinction is made between autologous transplantation (one's own, previously harvested cells) and allogeneic transplantation (donor cells).

This benefit is no blank cheque, however: HSCT is an invasive procedure with considerable risks. In the allogeneic variant, graft-versus-host disease (GvHD) can occur, in which the transferred immune cells attack the recipient's tissue; severe infections and complications from the preparatory conditioning add to this. The point is: even the best-evidenced stem cell application is demanding, carefully tied to specific indications, and belongs in specialised centres - not in a wellness or anti-ageing clinic.

Established standard therapy for defined blood and immune disorders
Autologous (one's own cells) vs. allogeneic (donor cells)
Serious risks include: graft-versus-host disease, infections, conditioning consequences
Belongs in specialised centres with a clear medical indication

What research really shows for new applications

Beyond blood and immune disorders, stem cells are being researched intensively - for example in heart failure, osteoarthritis, spinal cord injuries, neurodegenerative diseases, or autoimmune conditions. Much of this is scientifically legitimate and is in preclinical models or early clinical trials. “Promising in the study” does not, however, lead to “proven effective in the patient”. For most of these widely advertised areas of application, robust proof from controlled clinical trials in humans is still lacking.

This is precisely where a dangerous gap arises: commercial providers translate early laboratory findings or individual anecdotal reports into market-ready promises of cure. A critical literature review in the journal International Health (2022) describes how unproven offerings are increasing worldwide and attracting patients with severe illnesses, without efficacy being established. Such claims should be read as marketing statements, not as scientific fact - even when they are backed up with study citations or anecdotal reports.

Active, serious research is underway - mostly preclinical or in early trial phases
“Promising in the study” is not the same as “proven effective in humans”
For most widely advertised indications, robust human evidence is lacking
Promises of cure from commercial clinics are marketing, not proof of efficacy

Regulatory status: approved, investigational - or not at all

The honest regulatory status is decisive. In the United States, according to the FDA, only blood-forming stem cell products (from bone marrow, peripheral blood, or umbilical cord blood) are approved for defined diseases of the blood and immune system. The FDA explicitly warns: anyone asked to pay for a stem cell product outside a clinical trial is, in all likelihood, being deceived and is being offered a product illegally.

In Europe, stem cell treatments in which cells are substantially manipulated or used for a different purpose are considered Advanced Therapy Medicinal Products (ATMP) and must be approved centrally via the European Medicines Agency (EMA). In March 2025, the EMA and national authorities - in Germany the Paul-Ehrlich-Institut - publicly warned against commercially marketed, unapproved ATMP and emphasised: only treatment with approved products or within authorised clinical trials is recommended. In other words: much of what is sold as “stem cell therapy” is neither approved nor anchored in a vetted study.

USA: only blood-forming stem cell products approved for blood/immune disorders (FDA)
FDA warning: payment outside a study points to an illegal/deceptive offering
EU: substantially manipulated stem cells = ATMP, central approval via the EMA required
Germany: the Paul-Ehrlich-Institut warns (with EMA/HMA) against unapproved ATMP offerings

Risks of the grey market and “stem cell tourism”

When established medicine promises no benefit, some patients travel to countries with weaker regulation to receive paid stem cell “treatments” there - the phenomenon is called “stem cell tourism”. The aforementioned review names, among others, the USA, China, India, Thailand, and Mexico as important provider markets and describes typical problems: patchy informed consent, lack of follow-up care, misleading online advertising, and travel-related health risks.

The concrete medical dangers are documented and serious. The FDA points to severe cases of harm, including blindness after injection of stem cells into the eye, a tumour growth after an injection into the spinal cord, and hospitalisations from bacterial infections from contaminated products. Added to this are uncontrolled cell proliferation, rejection reactions, the risk of tumour formation, high costs without reimbursement, and - not least - the emotional disappointment when an expensive promise of cure fails. The sober assessment is: the hype is large, the proven effect for most advertised applications small, and the risks are real.

“Stem cell tourism”: paid offerings in more weakly regulated countries
Documented harms include: blindness, tumour formation, severe infections, hospitalisations
Frequently: inadequate informed consent, lack of follow-up care, misleading advertising
Financial burden and false hope as additional consequences

Frequently asked questions

Is stem cell therapy generally scientifically recognised?: Only partly. What is recognised and established is above all haematopoietic stem cell transplantation for defined blood and immune disorders. Many other commercially advertised “stem cell therapies” - for example against osteoarthritis, ageing, or neurological diseases - are by contrast experimental or unproven and not approved.
Why do authorities warn against some stem cell offerings?: Because many offerings are marketed without robust proof of efficacy and outside authorised clinical trials. The FDA and Paul-Ehrlich-Institut/EMA point to real risks such as severe infections, tumour formation, or blindness, as well as financial burden and false hope. Payment outside a study is, according to the FDA, a warning sign.
What should I do if I am offered a stem cell treatment?: This page does not replace medical advice. As a general principle: check the approval status, ask whether it is an authorised clinical trial, and discuss the offering with independent specialist physicians before making a decision.

Sources

This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.

← All guide articles